Boston Scientific Urology

Newly published data from the VAPEUR RCT demonstrates that Rezūm™ Water Vapour Therapy can be adopted in routine practice for patients who would otherwise be directed to combination therapy. VAPEUR randomised clinical trial at 1-year reports that Rezūm Therapy can serve as an effective alternative to dual drug therapy, after alpha blockers fail, for the treatment of symptomatic BPH in sexually active men. CE0344

Data from the VAPEUR RCT at 1 year demonstrates that Rezūm™ Water Vapour Therapy preserves sexual function. Sexual function is an important consideration for many men treated for BPH. In the VAPEUR randomised clinical trial, sexual function remained stable with Rezūm Therapy (+1.1±16.9) and combination therapy (-5.2±16.4). CE0344

Published now: The VAPEUR trial is the first randomised clinical trial to directly compare Rezūm™ Water Vapour Therapy to combination drug therapy in BPH. At 1 year, Rezūm demonstrated superior symptom relief while preserving sexual function — adding important comparative evidence to the BPH treatment landscape.

Data from the VAPEUR study at one year demonstrated that RezūmTM Water Vapour Therapy provides superior BPH symptom relief. LUTS relief (measured by IPSS) was superior with Rezūm Therapy compared to combination therapy ( -4.6 points, p=0.0004). CE0344

Data from the VAPEUR Randomised Clinical Trial met its primary endpoints and demonstrated that, at one year, Rezūm™ Water Vapour Therapy provides superior BPH symptom relief outcomes and greater quality-of-life improvement versus combination therapy in sexually active men, while preserving sexual function.

New randomised clinical evidence in BPH. In the VAPEUR study, LUTS symptom relief, measured by International Prostate Symptom Score (IPSS), was superior Rezūm™ Therapy compared to combination therapy. These findings support Rezūm™ as a potential first-line alternative to combination therapy after alpha-blocker failure.